| Autor: |
George Bello, Matthew Kagoli, Sikhona Chipeta, Andrew Auld, Joy C-W Chang, Joshua R DeVos, Evelyn Kim, Jonathan Mkungudza, Danielle Payne, Michael Eliya, Rose Nyirenda, Andreas Jahn, Taziona Mzumara, Bernard Mvula, Sufia Dadabhai, Ireen Namakhoma, Yusuf Babaye, Amalia Giron, Michael R Jordan, Silvia Bertagnolio, Gabrielle O’Malley, Nellie Wadonda-Kabondo |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Antiviral therapy. 27(4) |
| ISSN: |
2040-2058 |
| Popis: |
Background Information on HIV drug resistance (HIVDR) prevalence in people newly diagnosed with HIV is limited. We implemented a cross-sectional study to estimate HIVDR prevalence among pregnant women recently infected with HIV in Malawi. Methods The HIVDR study was nested within a routine antenatal clinic (ANC) sentinel surveillance survey. Dried blood spot samples were tested for recent infection using a limiting antigen antibody assay together with HIV viral load testing. HIV-1 protease and reverse transcriptase were sequenced using Sanger sequencing. Drug susceptibility was predicted using Stanford HIVdb algorithm (version 8.9). Weighted analysis was performed in Stata 15.1. Results Of the 21,642 pregnant women enrolled in the ANC survey, 8.4% (1826/21,642) tested HIV positive. Of these, 5.0% (92/1826) had recent HIV infection, and 90.2% (83/92) were tested by PCR. The amplification and sequencing success rate was 57.8% (48/83). The prevalence of any HIVDR was 14.6% (5/45) (95% CI: 4.7–36.8%), all of which indicated HIVDR to nonnucleoside reverse transcriptase inhibitors (NNRTIs). HIVDR to nucleoside reverse transcriptase inhibitors was 7.9% (2/45) (95% CI: 1.4–34.6%). Resistance to protease inhibitors currently in use in Malawi was not observed. Conclusions Despite the low number of cases with presumed TDR, our study hints that resistance to NNRTIs was high, above the 10% target for regimen change. Further investigation is needed to establish the exact magnitude of presumed TDR among women recently infected with HIV. These findings support the transition to an integrase inhibitor-based first-line regimen for patients initiating or on ART. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
